Top Medical News
Stephen Padilla, 2 hours ago
Despite having guideline recommendations to receive oral anticoagulation (OAC) therapies, a majority of patients with atrial fibrillation (AF) are not treated with an OAC in current community practice, a recent study has found. Additionally, nontreatment is linked to factors unrelated to recommended stroke risk stratification, such as AF duration, chronicity and comorbidity.
3 hours ago
The rates of switch and treatment response are similar among lithium monotherapy, sertraline monotherapy and lithium-sertraline combination therapy in patients with bipolar II depression, according to a recent study. Moreover, the combination therapy group has a higher dropout rate, without any treatment acceleration advantage.
4 hours ago
Optimal continuous positive airway pressure (CPAP) treatment lowers aldosterone excretion in patients with uncontrolled resistant hypertension (RHT), but its effect on intention-to-treat is borderline, a recent study has found.
Roshini Claire Anthony, 14 hours ago

The introduction of direct antiviral agents (DAAs) substantially improved sustained virological response (SVR) in patients with hepatitis C virus (HCV), a recent study found.

14 hours ago
There appears to be a dose-dependent inverse association between the aggregated healthy lifestyle factors and the risk of gastric adenocarcinoma among individuals who are highly exposed to Helicobacter pylori infection, according to the results of the Singapore Chinese Health Study.
Pearl Toh, 18 hours ago
The everolimus-eluting bioresorbable vascular scaffold (BVS), Absorb, was noninferior to Xience metal stent for target lesion failure (TLF) by 1 year and between 1–2 years, but was associated with significantly higher cumulative TLF rates by 25 months, according to the ABSORB III trial presented at the ACC.17 in Washington, DC, US.
Jairia Dela Cruz, 18 hours ago
The oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib has therapeutic potential in relapsed or refractory advanced-stage marginal-zone lymphoma (MZL), demonstrating durable responses and favourable risk-benefit profile, according to the results of an open-label phase II trial.
Special Reports
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
28 Mar 2017
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Probiotics have been used by humans to promote good health
since a century ago. They are also increasingly used in a variety of clinical conditions and this article summarizes some of these uses. 
20 Mar 2017
At the recent Asian Pacific Digestive Week (APDW) 2016 held in Kobe, Japan, three prominent international experts shared their views on gastroesophageal reflux disease (GERD) and the challenges of its management.
20 Mar 2017
At a recent lunch satellite symposium held in conjunction with the Malaysian Society of Anaesthesiologists & College of Anaesthesiologists Annual Scientific Congress 2016, Dr Choo Chee Yong talked about the current perspectives and clinical uses of oxycodone in managing postoperative pain.
17 Mar 2017
On 6 November 2016, in conjunction with the first year anniversary of vortioxetine (Brintellix®, Lundbeck) in Malaysia, two distinguished speakers, Professor Gin S Malhi and Dr Pranab Kalita shared updates on depression and the use of vortioxetine in order to help patients with major depressive disorders (MDD) to return to their premorbid functional states. The session was followed by three case presentations.
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
13 Mar 2017
With the drive to share the current healthcare expert’s practices in managing different types of infections, Mundipharma conducted its 1st PLUS (Pharmacy cLinical UpdateS) Summit by inviting a group of consultants to share the role of povidone-iodine (PVP-I) in infection prevention and management with the community pharmacists on 15th–16th October 2016 in Port Dickson.
Conference Reports
Pearl Toh, 30 Mar 2017
The everolimus-eluting bioresorbable vascular scaffold (BVS), Absorb, was noninferior to Xience metal stent for target lesion failure (TLF) by 1 year and between 1–2 years, but was associated with significantly higher cumulative TLF rates by 25 months, according to the ABSORB III trial presented at the ACC.17 in Washington, DC, US.
Roshini Claire Anthony, 28 Mar 2017

The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.

Pearl Toh, 28 Mar 2017
Transcatheter aortic valve replacement (TAVR) is an effective and safe alternative to surgical aortic valve replacement (SAVR) for intermediate- and high-risk patients in the real world, with no significant difference in stroke and mortality rates at 1 year, and discharge to home being more common among TAVR patients, according to the ADVICE* study presented at the recent ACC.17 Scientific Session held in Washington, DC, US.
28 Mar 2017
Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.
28 Mar 2017
Podcast: Dr Marc Sabatine talks about the FOURIER Outcomes trial which shows lower CV events with the PCSK9 inhibitor evolocumab.
28 Mar 2017
Slideshow: Highlights from the American College of Cardiology 66th Annual Scientific Session (ACC)
Pearl Toh, 27 Mar 2017
Extended therapy with rivaroxaban was more effective than aspirin in reducing the risk of recurrent venous thromboembolism (VTE) with no significant increase in bleeding risk, according to data from the EINSTEIN CHOICE* study presented at the ACC.17 Scientific Session in Washington, DC, US.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!